<DOC>
	<DOCNO>NCT00006279</DOCNO>
	<brief_summary>The purpose study see safe give nevirapine ( NVP ) breast-feeding baby birth age 6 month determine dose NVP give . Breast-feeding show important physical mental health infant . This especially true first 6 month life . However , HIV-positive mother pas virus baby breast-feeding . Because risk , HIV-positive mother encourage formula-feed , breast-feed , baby . In develop country , however , woman afford formula-feed . If formula-feed , woman risk expose HIV status . These woman great need method low chance pas HIV baby . This study test NVP way .</brief_summary>
	<brief_title>The Safety Nevirapine When Given Breast-Feeding Babies From Birth Age 6 Months</brief_title>
	<detailed_description>Breast-feeding critical importance general health infant , well mother-infant relationship , special effort make retain practice even HIV pandemic . Breast-feeding associate low rate infant gastrointestinal infection protect high infant mortality respiratory gastrointestinal disease . These protective effect great first 6 month life . However , HIV transmit breast-feeding . HIV-infected woman whose circumstance permit choice breast- formula-feeding encourage formula-feed . But develop country HIV-infected woman afford formula-feed , know risk , choose breast-feed . In society , HIV-infected woman deviate cultural norm breast-feeding risk expose HIV status become prey negative social implication . For group woman , define strategy reduce risk transmit HIV infant essential . Based data previous study , study proposes test hypothesis NVP reduce breast-feeding transmission HIV . Pregnant HIV-positive woman take oral dose NVP onset labor . A second dose NVP give 48 hour first dose woman remain labor . Infants initiate breast-feeding randomize 1 3 study arm receive first dose NVP within 48 hour birth . Arm 1 receives NVP week , Arm 2 receives NVP twice week , Arm 3 receives NVP daily . There placebo control group . The first 18 infant enrol arm contribute pre- post- NVP dose blood sample pharmacokinetics . The remain infant contribute data safety pre-dose NVP level . Infants return clinic weekly visual assessment NVP toxicity . Women counsel stop breast-feeding infant end 6 month . Infants receive last dose NVP either 24 week age 1 week breast-feeding cessation , whichever occur first , follow-up visit infant 32 week old .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Inclusion Criteria Mothers may eligible study : Receive prenatal care King Edward VIII Hospital , Durban , St. Mary 's Hospital , Marianhill , South Africa ; polyclinics Chitungwiza District , Zimbabwe . Are pregnant least 30 week give birth . Are least 18 year age . Are HIVpositive 2 ELISA test . Have serious current previous problem pregnancy ( e.g. , seizure ) . Have fix home and/or work address . Plan deliver baby hospital clinic study base . Plan breastfeed baby . Infants may eligible study : Are born woman participate study . Weigh least 2.5 kg birth . Begin breastfeed 48 hour . Exclusion Criteria Mothers eligible study : Have AIDS serious illness . Are use illegal drug use alcohol long time . Are sensitive NVP . Have take nonnucleoside reverse transcriptase inhibitor past . Are use rifampin , rifabutin , ketoconazole , macrolides , cimetidine . Infants eligible study : Have jaundice ( yellow skin white eye ) require blood transfusion . Have serious lifethreatening condition ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Pregnancy Complications , Infectious</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Disease Transmission , Vertical</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Breast Feeding</keyword>
</DOC>